The new Combo Plus features anti-CD34 antibody biological coating, which helps in active vessel healing with improved deliverability for patients with complex coronary artery disease.

Once implanted, the biological coating on the outer surface of the dual therapy stent will immediately capture endothelial progenitor cells and starts the formation of an endothelial layer.  The accelerated healing process helps in earlier return of functionality, in addition to reducing adverse events in the long-term.

Bioabsorbable polymer’s directional coating is said to elute sirolimus to inhibit neointimal hyperplasia, in concert with the biological layer.

For better deliverability, Combo Plus uses an enhanced balloon catheter with a lower profile design, lubricious coating and reduced shaft diameters.

OrbusNeich board chairman David Chien said: "Our design improvements provide superior deliverability and powerful performance for complex daily practice.

“Combo Plus offers physicians a compelling new treatment option for patients with coronary artery disease."

In 2013, the company launched Combo DTS to stimulate endothelial coverage and control neointimal proliferation through the combination of pro-healing technology with an abluminal sirolimus drug elution delivered from a bioresorbable polymer that is completely dissipated within three months.

OrbusNeic markets its stents and balloons under the names of Azule, Scoreflex, Sapphire II, Sapphire II PRO and Sapphire II NC. Its Jade and Scoreflex PTA balloons will be used to treat peripheral artery disease.